BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• IPA Announces Pricing of $1.1 Million Public Offering of Common Shares

  ImmunoPrecise Antibodies Ltd. announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share.

  December 6, 2023

   · 

  4 min read
• Drug Development

  Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

  Syros Pharmaceuticals today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist.

  December 6, 2023

   · 

  8 min read
• Business

  Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors

  Abcuro, Inc. today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors.

  December 6, 2023

   · 

  2 min read
• VitriVax Receives $5M Grant for Vaccine Development

  Grant from Gates Foundation funds manufacturing capacity expansion and platform technology research

  December 6, 2023

   · 

  1 min read
• Deals

  Coya Therapeutics Announces $26.5 Million Private Placement

  Coya Therapeutics, Inc. announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock.

  December 6, 2023

   · 

  5 min read
• ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

  ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed journal, Diabetes, demonstrating that AIM2 and NLRP3 inflammasome activation contributes to development of atherosclerosis in two different animal models of type 1 diabetes.

  December 6, 2023

   · 

  6 min read
• Drug Development

  Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

  Century Therapeutics today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s Phase 1 clinical trial may proceed to assess CNTY-101.

  December 6, 2023

   · 

  9 min read
• Pharm Country

  Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

  Century Therapeutics today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1.

  December 6, 2023

   · 

  5 min read
• Business

  Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim

  Ten63 Therapeutics announced today a multi-target drug discovery collaboration with Boehringer Ingelheim.

  December 6, 2023

   · 

  2 min read
• Deals

  Danaher Completes Acquisition of Abcam

  Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”).

  December 6, 2023

   · 

  1 min read